Elemer Piros

GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake

GW Pharma Receives EU Regulatory Agency Panel Backing For Epidiolex

Aldeyra's Eye Inflammation Drug Aces Late-Stage Trial, Stock Rises 60%

GW Pharma Receives EU Regulatory Agency Panel Backing For Epidiolex

Aldeyra's Eye Inflammation Drug Aces Late-Stage Trial, Stock Rises 60%

Cantor Reiterates Bullish View On GW Pharmaceuticals Following Earnings

Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

Cantor Reiterates Bullish View On GW Pharmaceuticals Following Earnings

Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

Proteostasis Therapeutics Rallies On Genentech Licensing Agreement

Cantor Fitzgerald Lowers GW Pharmaceuticals Price Target

Elemer Piros Recent News

Global Blood's Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway

Cantor Fitzgerald Bullish On GW Pharmaceuticals, Sees 75% Upside Potential

Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'

GW Pharma's Epidiolex Becomes First CBD To Get DEA Rescheduling

Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals

Wall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment

Glaukos Has 84% Upside Potential In 2018, According To Cantor

Analyst: Weakness In Spark Therapeutics Is Overdone

After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target

Can Omeros Top-Line Growth Continue?

At Long Last, Dynavax Wins FDA Approval For Heplisav

Bluebird Bio Price Target Bumped To $58 On Directional Improvements

Analyst Sees 243% Upside For Corbus Pharma Following Positive Clinical Data

Spark Therapeutics: Inside The Dramatic FDA AdCom Meeting

Aerie Pharma's FDA Briefing Docs: Good News With No Surprises; Shares Scale a Record

Analyst Upgrades Zynerba, Encouraged By Prospects For Fragile X Phase 2 Study

What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?

Versartis' Somavaratan Still Has A Path Forward; Cantor Reiterates Buy

Is GW Pharma Now The Future Of Cannabis-Based Drugs?

Zynerba's Clinical-Trial Miss Devastates Stock Price

Canton Fitzgerald Reiterates Overweight Rating, $28 Price Target On Zynerba

Intercept Pharma Analysts See Growth Ahead, But Keep Underweight Rating For Now

Cantor Remains Confident On Ocular Therapeutix Despite Big Decline